Gene · 150
ADRA2A: adrenoceptor alpha 2A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADRA2A: adrenoceptor alpha 2A. Genes, record 150. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/150
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P08913 | Alpha-2A adrenergic receptor | 465 | 19 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 2631 | P08913 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 334 | P08913 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 334 | P08913 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 2631 | P08913 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3467 | P08913 | Espacenet |
| WO 2024251866 A1 | 2024-12-12 | 28 | P08913 | Espacenet |
| EP 4426287 A1 | 2024-09-11 | 1 | P08913 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 4791 | P08913 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3467 | P08913 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 196 | P08913 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs66
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALSEROXYLON | CHEMBL1201454 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| APRACLONIDINE | CHEMBL647 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| APRACLONIDINE HYDROCHLORIDE | CHEMBL1200379 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| AVIPTADIL | CHEMBL1981592 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| BRIMONIDINE | CHEMBL844 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| BRIMONIDINE TARTRATE | CHEMBL1200389 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| CELIPROLOL | CHEMBL27810 | Adrenergic receptor alpha-2 antagonist | ANTAGONIST | ChEMBL |
| CLONIDINE | CHEMBL134 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| CLONIDINE HYDROCHLORIDE | CHEMBL1705 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| DEXMEDETOMIDINE | CHEMBL778 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
1 to 10 of 66
See all 66 drugsTrials1,036
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07603596 | DEXMEDETOMIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT07585201 | DEXMEDETOMIDINE | ClinicalTrials.gov | ||
| NCT07573969 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07572656 | LABETALOL | ClinicalTrials.gov | ||
| NCT07569536 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07564531 | DEXMEDETOMIDINE | ClinicalTrials.gov | ||
| NCT07557680 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07542990 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07537894 | DEXMEDETOMIDINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07532733 | DEXMEDETOMIDINE | ClinicalTrials.gov |
1 to 10 of 1,036
See all 1,036 trialsNIH grants1,882
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADRA2A papers | Newest fiscal year |
|---|---|---|---|
| R01HL016037 | Molecular Regulation of Cardiovascular 7 TM Receptors | 8 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 6 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 5 | 2025 |
| R01MH084894 | Function of GPCR heteromeric complexes in brain | 5 | 2025 |
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 4 | 2025 |
| R01DA008863 | Regulation Of Opioid Receptor Signaling by Endogenous Peptides | 4 | 2025 |
| R01DK105448 | Genetic and Metabolic Basis of Familial Lipodystrophies | 4 | 2025 |
1 to 10 of 1,882Source NIH's project files
See all 1,882 nih grantsPapers2,435
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Conflicting Molecular Hallmarks of Lipedema Reflect Cell-Composition Confounding: A Reanalysis and Germline Reframing. | Cureus | 2026 | 42824866 | PubTator, text mining | PubMed |
| Guanfacine as a potential preventive therapy for chronic migraine: a mechanistic hypothesis. | Front Neurol | 2026 | 42824170 | PubTator, text mining | PubMed |
| Subtypes of Bladder-Innervating Sensory Neurons revealed by Immuno-Fluorescence In Situ Hybridization. | bioRxiv | 2026 | 42818607 | PubTator, text mining | PubMed |
| Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder. | Front Mol Neurosci | 2026 | 42781299 | PubTator, text mining | PubMed |
| In Silico and Molecular Docking Analysis of Benzyl Isothiocyanate from Salvadora persica as a Predicted Multi-Target Candidate for COVID-19 Host Responses. | Curr Issues Mol Biol | 2026 | 42651847 | PubTator, text mining | PubMed |
| TBX6 promotes proliferation, invasion, and migration in colorectal cancer: Integrated transcriptomic and protein interaction network analysis. | Gene | 2026 | 42401341 | PubTator, text mining | PubMed |
| Clinical Outcomes of Extended-Release Guanfacine in Adults With Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review. | Cureus | 2026 | 42388918 | PubTator, text mining | PubMed |
| Novel Perspective for Prognostic Stratification and Personalized Therapy in Breast Cancer Patients: Development of Cancer Stem Cells and Metabolism-Associated Prognostic Model. | Int J Womens Health | 2026 | 42358344 | PubTator, text mining | PubMed |
| Sympathetic immunomodulation suppresses liver metastasis by maintaining the balance between norepinephrine concentration and the α2a/β2-AR ratio. | Cell Mol Immunol | 2026 | 42332097 | PubTator, text mining | PubMed |
Deciphering the potential molecular network underlying nicotine- and its metabolite cotinine-induced myocardial infarction via network toxicology, molecular dynamics, and in vitro experimental validation. | Funct Integr Genomics | 2026 | 42319523 | PubTator, text mining | PubMed |
1 to 10 of 2,435
See all 2,435 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/150
GET https://conductscience.org/api/genes/v1/150/patents?page=2